Stand Up To Cancer: Fundraising that Benefits Cancer Research
Stand Up to Cancer (SU2C) brings together Dream Teams of the best and the brightest researchers across disciplines, institutions, countries and specialties to join in a unified fight against cancer with translational research.
Transforming Pancreatic Cancer to Treatable Disease
The newly announced SU2C-Lustgarten Foundation Pancreatic Cancer Convergence Dream Team is co-led by Penn Medicine's own director of Translational Research, Robert Vonderheide, MD, DPhil.
Calling on Penn Medicine's advances in the study of immunotherapy as an exciting new treatment option for leukemia and melanoma, this Dream Team hopes to apply a similar approach to treating pancreatic cancer.
Immunotherapy and Pancreatic Research Breakthroughs at Penn
- Engineered T Cells Destroy Leukemia Tumors
- Four-Week Vaccination Regimen Knocks Out Early Breast Cancer Tumors
- HIV Drug Reduces Graft-versus-Host Disease in Bone Marrow Transplant Patients
- Added Photodynamic Therapy Improves Survival for Mesothelioma Patients